ICP Panel Prep Flashcards
Adenosine Pharmacology
AV Node anti arrhythmic (produces transient atrioventricular nodal block)
Binds to a1 receptors in AV node, forces potassium out of the cell (hyperpolerises cell) + slows calcium flow in (slows conduction velocity through AV node).
Indications Adenosine
Regular SVT (Narror complex tachycardia)
Regular SVT with aberrancy of conduction (SVT-A)
Contraindications adenosine
Hx of second or third degree heart block or sick sinus syndrome (except for pt with functioning pacemaker)
Sinus node disease
Chronic obstructive lung disease (eg asthma)
Known Hypersensitivity
Precautions Adenosine
Current dipyramole therapy (Asantin, Persantin) - increases plasma levels / effects of adenosine
Pts on carbamazepine - increases level of AV block
Amiodorone Pharmacology
A class 3 anti arrhythmic agent
Blocks potassium channels that cause repolarisation at phase three of the cardiac action potential, which extends the duration of the action potential and the refractory period. This prolongation of the refractory period helps prevent reentrant arrhythmias.
Also has sodium and calcium channel blocking and beta adrenocepter blocking effects
Amiodorone indications
VF/ VT refractory to cardioversion
Sustained or recurrent VT
Amiodorone contraindications
VT with inadequate perfusion or in pregnancy
Known hypersensitivity to Amiodorone or Iodine
TCA overdose
Precautions Amiodorone
Nil of significance
Side effects Amiodorone
Hypotension (arterial vasodilation and negative inotropy effects) and bradycardia (from sodium, potassium, and calcium channels, as well as beta-adrenergic receptor blockade).
Atropine Pharmacology
Anticholinergic agent. Inhibits actions of acytocholyne on post gangleonic cholinergic nerves
Vagal blocker - allows sympathetic effect to increase SA node firing rate and increase conduction velocity through the AV node
Atropine Indications
Bradycardia with less than adequate perfusion
Organophosphate poisoning with excessive cholinergic effects
Nerve agent poisoning
Contraindications atropine
Nil
Precautions atropine
Atrial flutter
Atrial fib (increases SA node firing rate - atria already firing at high rate)
Do not increase hr over 100 (except in kids under 6)
Glaucoma
Side effects atropine
Tachycardia
Absolute contraindications to thrombolisis
Active bleeding or bleeding disorders
Severe uncontrolled BP > 180/110
Surgery or major trauma in past 6 week
GI/GU Bleeding in past 2-4 weeks
TIA/CVA in past 12 months
Prior intercranial haemorrhage
Suspected aortic dissection
Known malignant intracranial neoplasm
Relative Contraindications to Thrombolysis
Current anti coags
Traumatic or prolonged CPR >10 mins
Hx of chronic severe or uncontrolled hypertension
Advanced liver disease
Advanced metastatic cancer
Non compressible vascular puncture (eg fistula or central venous access)
Pregnancy or 1 week post partum
Magnesium Pharmacology
Magnesium acts as a smooth muscle relaxant by blocking calcium channel mediated contraction and decreasing acytocholine release (also through calcium channel blocking effects).
Asthma – Inhibits the release of acetylcholine at the neuromuscular junction and interferes with calcium influx into smooth muscle cells which leads to bronchodilation.
Torsade de point – Calcium channel blockage which prevents the prolongation of the QT interval. Suppresses early afterdepolarisations that lead to torsardes.
Eclampsia – Inhibits excitatory NMDA receptors, blocks calcium flow and neuroexcitation. Also causes cerebral vasodilatation (Cerebral vasoconstriction thought to play a role in eclamptic seizures).
Magnesium Indications
Torsardes de pointe
Eclampsia
Severe Preeclampsia
Pts with severe asthma unresponsive to salbutamol/ ipratroprium
Contraindications Magnesium
Known heart blocks
Known hypersensitivity
Impaired renal / hepatic function
Addison’s disease
Side effects magesium
Hypotension
Circulatory collapse
CNS and resp depression
Cardiac arrhythmias
Loss of deep tendon reflexes
Clopidogrel Pharmacology
Antiplatelet medication that inhibits platelet aggregation by irreversibly binding to the P2Y12 receptor on platelets, thereby preventing activation of the ADP mediated glycoprotein GP IIb/IIIa complex, which is necessary for platelet aggregation.
Enoxaparan Pharmacology
Low molecular weight heparin. Anticoagulant medication. Binds to and activates antithrombin III, a naturally occurring inhibitor of several clotting factors in the blood. primarily inhibits Factor Xa, a crucial enzyme in the coagulation cascade that converts prothrombin (Factor II) to thrombin (Factor IIa). Thrombin is responsible for converting fibrinogen into fibrin, the protein that forms the structural basis of a blood clot.
It is similar in structure and action to heparin. However, enoxaparin generally provides a greater safety profile and more predictable response when compared to heparin.
Heparin Pharmacology
Anticoagulant medication . Combines with antithrombin III (heparin co-factor), thrombosis is blocked through inactivation of activated factor X and inhibition of prothrombin’s conversion to thrombin. This also prevents fibrin formation from fibrinogen during active thrombosis. Heparin can prevent the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilising factor.
Tenectaplase Pharmacology
Tenecteplase is a tissue plasminogen activator that works by binding to the fibrin matrix of a thrombus and converting plasminogen to plasmin. This degrades the fibrin matrix of the thrombus and helps to restore perfusion to the affected vessel.